You are here: Industry Insights > Allergan

News List

Allergan sues Pfizer, saying it needs to cover its opioid liabilities for Kadian fiercepharma
August 06, 2018
Like a game of hot potato, painkiller Kadium has been passed around a group of pharma players in the last decade, from Alpharma to King Pharma, to Actavis and Allergan.
Allergan preludes major selloffs with $650M Almirall dermatology sale fiercepharma
August 06, 2018
Allergan, which is shopping assets to help turn its stock price around, has taken its first small step into selloff land.
Allergan, Molecular Partners’ AMD drug non-inferior to Lucentis pharmatimes
July 23, 2018
Allergan, Molecular Partners’ abicipar has shown non-inferiority to Novartis’ Lucentis but with fewer injections in late-stage trials involving patients with neovascular age-related macular degeneration.
Allergan’s experimental migraine drug hits trial targets pharmatimes
July 10, 2018
Allergan says its CGRP receptor antagonist atogepant has hit its primary target in a Phase IIb/III trial assessing its efficacy in preventing episodic migraine.
Old CEO, new chairman? Some Allergan investors want Pyott to come back: report fiercepharma
June 13, 2018
Last week, vocal investors called for Allergan CEO and Chairman Brent Saunders to give up one of those titles, making room for an outsider at the top. But sources said the outsider some shareholders have in mind is actually a former insider.
Axovant snatches Teva and Allergan execs to strengthen management pharmafile
June 07, 2018
Axovant has announced reinforcements to its management team with two new additions, snatching up Allergan’s current Chief Medical Officer Dr Gavin Corcoran as its new Executive Vice President of R&D, and Dr Michael Hayden, former Chief Scientific Officer
Allergan mauled by investors in public letter pharmafile
June 07, 2018
Last week, Allergan announced that a strategic review of its operations had led to a decision to divest its women’s health and infectious diseases unit – in doing so it hoped that investors would respond well to a leaner business.
Allergan recalls out-of-order contraceptive capsules pharmaceutical-technology
June 01, 2018
Allergan has issued a voluntary, US-wide recall of its Taytulla oral contraceptives after placebo and active capsules were found to have been placed in the incorrect order in sample packs.
Allergan acquires NMDA depression drug from Aptinyx collaboration fiercebiotech
May 29, 2018
Allergan has acquired an investigational NMDA receptor modulator discovered by Aptinyx, exercising its option under an ongoing collaboration, and plans to pair it with its rapastinel depression therapy currently under development.
Allergan R&D head still sees value in RORγt program after $533M write-off fiercebiotech
May 02, 2018
Allergan has been forced to write off the second of two drug candidates acquired when it took over Vitae Pharma less than two years ago.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 13 Next page